Adriamycin tolerance in human mesothelioma lines and cell surface NADH oxidase

Life Sciences

Volumn 73, Issue 9, 2003, Pages 1189-1198

  Hedges, Kathryn L ^a   Morré, Dorothy M ^b   Wu, Lian Ying ^b   Morre, D James ^c  

^a PURDUE UNIVERSITY CALUMET   (United States)

^b PURDUE UNIVERSITY   (United States)

^c PURDUE UNIVERSITY   (United States)

Author keywords

Adriamycin; Human mesothelioma cell lines; NADH oxidase

Indexed keywords

DOXORUBICIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL GROWTH; CELL MEMBRANE; CELL SURFACE; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG TOLERANCE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LUNG CARCINOMA; MESOTHELIOMA;

EID: 0037667821     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(03)00421-1     Document Type: Article

References (35)

1. Brightman A.O., Wang J., Miu R.K., Sun I.L., Barr R., Crane F.L., Morré D.J. A growth factor- and hormone-stimulated NADH oxidase from rat liver plasma membrane. Biochemica et Biophysica Acta. 1105:1992;109-117.
2. Bruno M., Brightman A.O., Lawrence J., Werderitsh D., Morré D.M., Morré D.J. Stimulation of NADH oxidase activity from rat liver plasma membranes by growth factors and hormones is decreased or absent with hepatoma plasma membranes. Biochemistry Journal. 284:1992;625-628.
3. Bucher J., Tien M., Morahouse L., Aust S. Redox cycling and lipid peroxidation: the central role of iron chelates. Fundamental Applied Toxicology. 3:1983;222-226.
4. Cantwell B., Franks C., Harris A. A phase II study of the platinum analogues JM8 and JM9 in malignant pleural mesothelioma. Cancer Chemotherapy Pharmacology. 18:1986;286-288.
5. Davis J. Ultrastructure of human mesotheliomas. Journal of National Cancer Institute. 52:1974;1715-1725.
6. Deliconstantinos G. Physiological aspects of membrane lipid fluidity in malignancy. Anticancer Research. 7:1987;1011-1022.
7. Doroshow J. Anthracycline antibiotic-stimulated superoxide, hydrogen peroxide, and hydroxyl radical production by NADH dehydrogenase. Cancer Research. 43:1983;4543-4551.
8. Falkson G., Vorobiof D., Lerner H. A phase II study of m-AMSA in patients with malignant mesothelioma. Cancer Chemotherapy Pharmacology. 11:1983;94-97.
9. Gayda D.P., Crane F.L., Löw H. Hormone effects on NADH-oxidizing enzymes of plasma membranes of rat liver. Proceedings of the Indiana Academy of Science. 86:1977;385-390.
10. Gianni L., Corden B., Myers C. The biochemical basis of anthracyclines toxicity and antitumor activity. Reviews in Biochemical Toxicology. 5:1983;1-82.
11. Goormaghtigh E., Pollakis G., Ruysschaert R. Mitochondrial membrane modifications induced by adriamycin-mediated electron transport. Biochemical Pharmacology. 32(5):1983;889-893.
12. Haidle C., McKinney S. Adriamycin-mediated introduction of a limited number of single-strand breaks into supercoiled DNA. Cancer Biochemistry Biophysics. 8:1986;327-335.
13. Jadot G. Anti-inflammatory activity of superoxide dismutases: inhibition of adriamycin induced edema in rats. Free Radical Research Communications. 2:1986;19-26.
14. Löw H., Crane F.L. Redox function in plasma membranes. Biochimica et Biophysica Acta. 515:1978;141-161.
15. Marx J. Drug resistance of cancer cells probed. Science. 234(4778):1986;818-820.
16. Morré D.J., Morré D.M. Preparation of mammalian plasma membranes by aqueous two-phase partition. BioTechniques. 7:1989;946-958.
17. Morré D.J. NADH oxidase: A multifunctional ectoprotein of the eukaryotic cell surface. Asard H., Bérczi A., Caubergs R. Plasma Membrane Redox Systems and Their Role in Biological Stress and Disease. 1998;121-156 Kluwer, Dordrecht.
18. Morré D.J., Brightman A.O. NADH oxidase of plasma membrane. Journal of Bioenergetics Biomembranes. 23:1991;469-489.
19. Morré D.J., Crane F.L., Eriksson L.C., Löw H., Morré D.M. NADH oxidase of liver plasma membrane stimulated by differic transferrin and neoplastic transformation induced by the carcinogen 2-acetylaminofluorene. Biochimica et Biophysica Acta. 1057:1991;140-146.
20. Morré D.J., Morré D.M., Paulik M., Batova A., Broome A.-M., Pirisi L., Creek K.E. Retinoic acid and calcitriol inhibition of growth and NADH oxidase of normal and immortalized human keratinocytes. Biochimica et Biophysica Acta. 1134:1992;217-222.
21. Morré D.J., Morré D.M., Wu L.-Y. Response to adriamycin of transplasma membrane electron transport in adrimaycin-resistant and non-resistant HL-60 cells. Journal of Bioenergetics and Biomembranes. 26:1994;137-142.
22. Morré D.J., Kim C., Paulik M., Morré D.M., Faulk W.P. Is the drug-responsive NADH oxidase of the cancer cell plasma membrane a molecular target for adriamycin? Journal of Bioenergetics and Biomembranes. 29:1997;269-280.
23. Rogers K., Carr E., Tokes Z. Cell surface-mediated cytotoxicity of polymer-bound adriamycin against drug-resistant hepatocytes. Cancer Research. 43:1983;2741-2748.
24. Rogers K., Tokes Z. Novel mode of cytotoxicity obtained by coupling inactive anthracycline to a polyer. Biochemical Pharmacology. 33:1984;605-608.
25. Silvertrini R., DiMarco A., Dasdia T. Interference of daunomycin with metabolic events of the cell cycle in synchronized cultures of rat fibroblasts. Cancer Research. 30:1970;966-973.
26. Silvertrini R., Lenaz L., Gronzo C.D. Correlations between cytotoxicity, biochemical effects, drug effectiveness of daunomycin and adriamycin on Sarcoma 180 ascites in mice. Cancer Research. 33:1973;2954-2958.
27. Smith P.K., Krohn R.I., Hermanson G.T., Mallia A.K., Gartner R.H., Provenzano E.K., Fujimoto E.K., Goeke N.M., Olson B.J., Klenk D.C. Measurement of protein using bicinchoninic acid. Analytical Biochemistry. 150(1):1985;76-85.
28. Sugawara L., Kataoka I., Morishita Y., Hamada H., Tsuruo T., Itoyama K.S., Mori S. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. Cancer Research. 48(7):1988;1926-1929.
29. Sun I.L., Crane F.L., Löw H., Grebing C. Inhibition of plasma membrane NADH dehydrogenase by adriamycin and related anthracycline antibiotics. Journal of Bioergenitcs Biomembranes. 16:1984;209-221.
30. Sun I.L., Crane F.L., Chou J.Y. Modification of transmembrane electron transport activities in plasma membranes of simian virus 40 transformed pineal cells. Biochimica et Biophysica Acta. 886:1986;327-336.
31. Thornalley P., Bannister W., Bannister J. Reduction of oxygen by NADH/NADH dehydrogenase in the presence of adriamycin. Free Radical Research Communications. 2:1986;163-171.
32. Tritton R.R., Yee G. The anticancer agent adriamycin can be actively cytotoxic without entering cells. Science. 217:1982;248-250.
33. Tsuruo T., Ilda-Salto H., Kawabata H., Oh-Hara T., Hamada H., Utakojl T. Characteristics of resistance to adriamycin in human myelogenous leukemia K562 resistant to adriamycin and in isolated clones. Japanese Journal of Cancer Research. 77:1986;682-692.
34. Whitaker D., Shilkin K., Walters H. Cytologic and tissue culture characteristics of asbestos-induced mesothelioma in rats. Acta Cytology. 28:1984;185-189.
35. Zijlstra J., deVries E., Muskiet F., Martini I., Timmer-Bosscha H., Mulder N. Influence of docosahexaenoic acid in vitro on intracellular adriamycin concentration in lymphocytes and human adriamycin-sensitive and -resistant small-cell lung cancer cell lines, and on cytotoxicity in the tumor cell lines. International Journal of Cancer. 40:1987;850-856.